Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
Abstract: A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.
Type:
Grant
Filed:
December 5, 2002
Date of Patent:
May 15, 2012
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
Type:
Grant
Filed:
April 24, 2008
Date of Patent:
February 7, 2012
Assignee:
Sangamo Biosciences, Inc.
Inventors:
Russell DeKelver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for (?-1,6-glucan.
Type:
Grant
Filed:
August 6, 2010
Date of Patent:
January 24, 2012
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Antonio Cassone, Antonella Torosantucci
Abstract: Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.
Type:
Grant
Filed:
July 9, 2010
Date of Patent:
December 6, 2011
Assignee:
Sangamo Biosciences, Inc.
Inventors:
Alan P. Wolffe, Elizabeth J. Wolffe, legal representative, Trevor Collingwood, Philip D. Gregory, Andrew Snowden, Fyodor Urnov
Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.
Abstract: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.
Type:
Grant
Filed:
January 9, 2008
Date of Patent:
September 6, 2011
Assignee:
Sangamo Biosciences, Inc.
Inventors:
H. Steve Zhang, Philip D. Gregory, Edward J. Rebar
Abstract: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.
Type:
Grant
Filed:
May 23, 2008
Date of Patent:
August 30, 2011
Assignee:
Genzyme Corporation
Inventors:
Alejandra E. Arbetman, Michael A. Lochrie
Abstract: Two different strains of Cordyceps sinensis are placed at two different locations in a medium containing purified rattle snake venom and the two strains are allowed to grow until they meet in a boundary zone where a hybrid strain is formed due to exchange of genetic material. The hybrid strain is allowed to grow and is harvested and can be analyzed for the presence and quantity of desired medicinal substances. The amount of N6-(2-hydroxyethyl)-adenosine in a Cordyceps sinensis strain or product sample is a reliable indicator of the overall health benefiting qualities of the strain or sample. Strains of Cordyceps sinensis, are grown in a substrate at 20 to 22° C. at sea level atmospheric pressure for 28 to 30 days in diffuse light, and thereafter in an atmosphere containing approximately 50% of oxygen of the sea level atmosphere, at approximately 3° C.
Type:
Grant
Filed:
July 30, 2008
Date of Patent:
August 30, 2011
Assignee:
Aloha Medicinals Inc.
Inventors:
Phillip D. Cleaver, John C. Holliday, Megan Loomis Powers
Abstract: A method of inserting a lipid-linked moiety into a lipid assembly, such as a planar lipid monolayer or bilayer, a spherical lipid vesicle, a micelle, or an emulsion envelope monolayer is described. In the method, the lipid assembly and the lipid-linked moiety are contacted in the presence of microwave irradiation to permit the lipid-linked moiety to become associated with the lipid assembly. In one embodiment, the lipid assembly is a liposome and the lipid-linked moiety is a lipid-polymer. Compositions comprised of a lipid layer and of a lipid-linked moiety, prepared in accord with the method, are also described.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
July 26, 2011
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem
Abstract: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
Type:
Grant
Filed:
May 23, 2007
Date of Patent:
May 31, 2011
Assignee:
Sangamo BioSciences, Inc.
Inventors:
Dale Ando, Michael C. Holmes, Gary Ka Leong Lee
Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.
Abstract: Disclosed herein are zinc finger proteins that bind to target sites in a plant gamma-tocopherol methyl transferase (GMT) gene; compositions comprising these GMT-targeted zinc finger proteins and methods of making and using such zinc finger proteins. Also disclosed are methods for modulating the alpha-tocopherol content in various plant organs, particularly seeds, in transgenic plants.
Type:
Grant
Filed:
April 17, 2003
Date of Patent:
May 24, 2011
Assignee:
Sangamo Biosciences, Inc.
Inventors:
Guofu Li, Qiang Liu, Andrew Jamieson, Edward Rebar, Mylavarapu Venkatramesh